Fig. 6: Met inhibits cell viability and cell cycle via the SOX4/TGF-β/Smad signaling axis in BPH-1 and WPMY-1 cells.
From: TNF-α modulates cell proliferation via SOX4/TGF-β/Smad signaling in benign prostatic hyperplasia
A, B WB analysis of SOX4 protein expression in BPH-1 and WPMY-1 cells treated with Met (0, 5, and 10 mM), retrospectively. C BPH-1 and WPMY-1 cells were plated in 96-well plates (3 × 103 cells/well) overnight. Then, BPH-1 and WPMY-1 cells were treated with doses of Met (0, 1, 5, 10, and 20 mM) for different time points (0, 24, 48, and 72 h). Cells viability was determined by CCK-8 test. D BPH-1 and WPMY-1 cells were plated in 6-well plates (2 × 105 cells/well) overnight. Then, BPH-1 and WPMY-1 cells treated with Met (0, 5, and 10 mM) for 3 days, and harvested for cell cycle test via flow cytometry. E, F WB analysis of TGF-β/Smad pathway protein expression in BPH-1 and WPMY-1 cells treated with Met (0, 5, and 10 mM) for 3 days. G WB analysis of EMT marker expression in BPH-1 cells treated with Met (0, 5, and 10 mM) for 3 days. H WB analysis of fibrosis marker expression in WPMY-1 cells treated with Met (0, 5, and 10 mM) for 3 days. Data are expressed as the means ± SEMs (*p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant).
